javanz
Posted - 18 hours ago
$BIXT So is big money stifling a medicinal cure of all cures imagining something that can nip it the bud
History101
Posted - 04/24/24
$BIXT anyone know the reason for today's drop?
flowerchefstocks
Posted - 04/12/24
@OCH11 Love this article b/c it really encapsulates how $GALT has become the new golden child in NASH/MASH https://www.insiderfinancial.com/post/galectin-therapeutics-galt-a-discount-opportunity-moving-on-analysts-upgrade Looks like $MDGL is old news now that they got approval. Not hating on MDGL but while GALT's drug might be better its an intravenous medicine versus a pill. If belapectin was a pill it would be perfect but dont see them accomplishing this. Unfortunately $GLTO and $BIXT are the ones that have the oral #galectin blockers
flowerchefstocks
Posted - 04/12/24
@mpier $BIXT seems to be getting a lift from $GALT shareholders that understand the concept of diversification of the Galectin-3 druggable target. An oral Gal-3 blocker would experience better uptake than Belapectin with its intravenous formulation assuming it was a better drug.
mpier
Posted - 04/11/24
$BIXT What's cooking hare? Not many know about BIXT. Only 181 watchers
History101
Posted - 04/10/24
$BIXT 533k shares traded so far today, up 11%, 6.2x normal volume and it is only 2:20pm ET. Someone wants our shares, Long!! Awesome...
javanz
Posted - 04/07/24
$BIXT Further more: Point to note, in Medical Astronomy; the light pattern woven by the Spin Point control the Pressure Point on the Cellular Surface in such a way that the pressure fluctuation are adjusted during its operations so that the new cell are perfectly balanced with all surrounding tissues.
javanz
Posted - 04/07/24
$BIXT The proper ratio between molecular density forms and the noise temperature patterns allow for light bubble parameters to be built around the main domain walls within which spin point regeneration can begin.
History101
Posted - 04/05/24
$BIXT 183 watchin 4/5/2024
History101
Posted - 04/05/24
$BIXT look at the 1week chart: volume increasing, price per share up nearly 30% in one week: someone wants our shares!! GLTALs!!
StockHakker
Posted - 04/04/24
$BIXT Why did the company increase (Dare I say dilute) 2 days ago: https://stock-scan.io/OSASGraph/BIXT
pauly815
Posted - 03/28/24
$BIXT is this moving? A co-worker brought it up so I read into the company’s projects.
Seems interesting but the price action is lacking….
richapd
Posted - 03/25/24
$BIXT David Platt CEO bought 3,559,289 sh at 0.135 on 1/16/24 for a total of $19,693,423. He obviously has faith in Bioxytran.
richapd
Posted - 03/25/24
$BIXT David Platt, CEO, purchased 3,559,289 Sh at 0.135 on 1/26/24 for a total amount of $19,693,423. Another 3 directors each purchased on 10/31/23 77721 sh each at 0.142. They must be bullish about the company and what is coming in the near future. I saw this information posted in my Fidelity account.
lianamic
Posted - 03/15/24
Bioxytran, Inc. ($BIXT) leads in clinical-stage pharmaceuticals, focusing on glycovirology, hypoxia, and degenerative diseases with advanced carbohydrate drug design. With a market cap of $20.62 million and 165.59 million outstanding shares, it's a key player in healthcare innovation. The 30-day average volume of 80,144 reflects growing interest. Trading in a 52-week range of 0.071 to 0.55, its previous close price was $0.1245. With authorised shares at 300 million and a float of 28.69 million, Bioxytran is poised for transformative advancements in medical science, offering hope for novel treatments against viruses and degenerative conditions, ultimately enhancing quality of life. #stockmarket #investing #trading #stocktowatch #stocktobuy #smallcaps #pennystocks #otcstockstowatch #otcstocklegends #beststockstowatch #Hypoxia #ViralDiseases #Pharmaceuticals #Bioxytran
lianamic
Posted - 03/14/24
Bioxytran, Inc. ($BIXT) continues to forge ahead in the biotech landscape with a market cap of $19.53 million and 165.58 million outstanding shares. Its average volume over the past 30 days stands at 78,867, showcasing consistent market interest. With a wide 52-week range from $0.071 to $0.55, bioxytran exhibits resilience and potential for growth. The company's authorised shares amount to $300 million, with a float of $28.69 million, positioning it strategically for future developments in the biotech sector. #stockmarket #investing #trading #stocktowatch #stocktobuy #smallcaps #pennystocks #otcstockstowatch #otcstocklegends #beststockstowatch #Hypoxia #ViralDiseases #Pharmaceuticals #Bioxytran
lianamic
Posted - 03/13/24
Bioxytran ($BIXT) is at the forefront of clinical-stage pharmaceutical innovation, targeting glycovirology, hypoxia, and degenerative diseases. With a market cap of $20.6 million and 165.58 million outstanding shares, it's positioned to revolutionise healthcare. The company's focus on carbohydrate drug design aims to eliminate viruses and extend lifespans. Trading on the OTC market, Bioxytran boasts an average volume of 78,068 over 30 days and a 52-week range of 0.071 to 0.55, signalling its dynamic presence in the industry. #stockmarket #investing #trading #stocktowatch #stocktobuy #smallcaps #pennystocks #otcstockstowatch #otcstocklegends #beststockstowatch #Hypoxia #ViralDiseases #Pharmaceuticals #Bioxytran
lianamic
Posted - 03/12/24
Bioxytran, Inc. ($BIXT) stands strong with a market cap of $19.04 million and 165.58 million outstanding shares. In the OTC market, its dynamic presence is emphasised by a 52-week range of 0.071–0.55. With authorised shares amounting to $300 million and a float of 28,687,245, Bioxytran is strategically positioned for innovative advancements in glycovirology and hypoxia. #stockmarket #investing #trading #stocktowatch #stocktobuy #smallcaps #pennystocks #otcstockstowatch #otcstocklegends #beststockstowatch #Hypoxia #ViralDiseases #Pharmaceuticals #Bioxytran
lianamic
Posted - 03/11/24
Bioxytran ($BIXT) is a trailblazing force in pharmaceuticals, advancing glycovirology, hypoxia, and degenerative disease treatments. With a market cap of $18.81 million and 165.58 million outstanding shares, Bioxytran's impact is evident. Averaging 75,024 in the last 30 days, it operates within a wide 52-week range of 0.071 to 1.05. Authorised for 300 million shares, its float of 28,687,245 signals a strategic approach to healthcare innovation. #stockmarket #investing #trading #stocktowatch #stocktobuy #smallcaps #pennystocks #otcstockstowatch #otcstocklegends #beststockstowatch
lianamic
Posted - 03/08/24
Bioxytran, Inc. ($BIXT), an OTC-listed powerhouse, is making waves in pharmaceuticals. With a market cap of $19.87 million and 165.59 million outstanding shares, it's a key player in the biotech domain. The 52-week range of $0.071-$1.05, authorised shares at 300 million, and a float of 28.69 million underline Bioxytran's potential for impactful advancements. The average volume of 74,078 emphasises growing market interest in this dynamic biotech entity. 🚀 Access the website ➡️ www.bioxytraninc.com #stockmarket #investing #trading #stocktowatch #stocktobuy #smallcaps #pennystocks #otcstockstowatch #otcstocklegends #beststockstowatch
lianamic
Posted - 03/07/24
Bioxytran, Inc. ($BIXT) is a dynamic force with a market cap of $19.87 million and 165.59 million outstanding shares. The 52-week range of $0.071–$1.05 and an average volume of 62,545 reflect their resilient presence. With 300 million authorised shares and a float of 28,687,245, Bioxytran is strategically positioned for growth in the biotech industry. #stockmarket #investing #trading #stocktowatch #stocktobuy #smallcaps #pennystocks #otcstockstowatch #otcstocklegends #beststockstowatch
History101
Posted - 03/06/24
$BIXT lovin my 11 cent cost basis...GLTALs!!
History101
Posted - 03/06/24
$BIXT 179 watchin 3/6/2024
lianamic
Posted - 03/05/24
Bioxytran, Inc. ($BIXT) is at the forefront of clinical-stage pharmaceutical innovation, leveraging platform technologies in glycovirology, hypoxia, and degenerative diseases. With a market cap of $18.43 million and 165,585,911 outstanding shares, they aim to eliminate viruses and extend lifespans through carbohydrate drug design. Notably, the 52-week range of 0.071–1.05, an authorised share count of 300,000,000, and a float of 28,687,245 highlight the dynamic nature of Bioxytran's presence in the biotech sector. #stockmarket #investing #trading #stocktowatch #stocktobuy #smallcaps #pennystocks #otcstockstowatch #otcstocklegends #beststockstowatch
jacknyak34
Posted - 03/05/24
$BIXT Bioxytran focuses on addressing hypoxia in humans, a critical condition caused by oxygen deficiency. With a market cap exceeding $18.4M and over 165.5M outstanding shares, they lead in developing therapeutic drugs to combat hypoxia-related issues. #StockMarket #Stocks #Investing #Traders #MarketWatch #MarketUpdate #BullMarket
